Hydroxyurea

Generic Name
Hydroxyurea
Brand Names
Droxia, Hydrea, Siklos, Xromi
Drug Type
Small Molecule
Chemical Formula
CH4N2O2
CAS Number
127-07-1
Unique Ingredient Identifier
X6Q56QN5QC
Background

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Indication

Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
Associated Therapies
Chemoradiotherapy, Radiation Therapy
Clinical Trials
Related News

Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis

First Posted Date
2017-02-23
Last Posted Date
2017-02-23
Lead Sponsor
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
Target Recruit Count
30
Registration Number
NCT03062501
Locations
🇧🇷

Hemorio, Rio de Janeiro, Brazil

Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies

Phase 2
Completed
Conditions
Sickle Cell Anemia
Interventions
Drug: Hydroxyurea
First Posted Date
2017-01-13
Last Posted Date
2021-06-25
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
58
Registration Number
NCT03020615
Locations
🇺🇸

Emory University/Children's Health Care of Atlanta, Atlanta, Georgia, United States

🇺🇸

University of Mississippi Medical Center, Jackson, Mississippi, United States

🇺🇸

University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

and more 1 locations

Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.

First Posted Date
2016-11-08
Last Posted Date
2016-11-28
Lead Sponsor
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Target Recruit Count
30
Registration Number
NCT02957760
Locations
🇫🇷

CHNO des Quinze-Vingts, Paris, France

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

First Posted Date
2016-09-14
Last Posted Date
2021-09-08
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
110
Registration Number
NCT02899169
Locations
🇨🇳

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Mobile-Directly Observed Therapy on Adherence to Hydroxyurea

First Posted Date
2016-07-26
Last Posted Date
2024-06-12
Lead Sponsor
Muhimbili University of Health and Allied Sciences
Target Recruit Count
98
Registration Number
NCT02844673
Locations
🇹🇿

Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia

Not Applicable
Active, not recruiting
Conditions
Sickle Cell Anemia
Interventions
Procedure: TCD examination
Drug: Hydroxyurea
First Posted Date
2016-05-12
Last Posted Date
2024-02-06
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
283
Registration Number
NCT02769845
Locations
🇩🇴

Encargada del Servicio de Hematología-Oncología Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

First Posted Date
2016-05-02
Last Posted Date
2023-10-12
Lead Sponsor
Emory University
Target Recruit Count
10
Registration Number
NCT02757885
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)

Phase 2
Terminated
Conditions
Hemoglobin SC Disease
Interventions
Drug: Hydroxyurea
First Posted Date
2015-12-29
Last Posted Date
2020-01-27
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
1
Registration Number
NCT02640573
Locations
🇺🇸

University of Texas Houston, Houston, Texas, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

EXTEND EXpanding Treatment for Existing Neurological Disease

Phase 2
Active, not recruiting
Conditions
Sickle Cell Anemia
Interventions
Drug: Hydroxyurea
First Posted Date
2015-09-22
Last Posted Date
2024-01-18
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
100
Registration Number
NCT02556099
Locations
🇯🇲

Sickle Cell Unit, Kingston, Jamaica

Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)

First Posted Date
2015-06-24
Last Posted Date
2015-06-24
Lead Sponsor
University of Leipzig
Target Recruit Count
113
Registration Number
NCT02480608
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy